Cardiff Oncology, Inc. (CRDF)Healthcare | Biotechnology | San Diego, United States | NasdaqCM
1.80 USD
+0.11
(6.509%)
⇧
(April 17, 2026, 4 p.m.
EDT)
After hours: 1.83 +0.03 (1.661%) ⇧ (April 17, 2026, 7:59 p.m. EDT) Short-term: ★★★☆☆ | Long-term: ★☆☆☆☆ | Dividends: ☆☆☆☆☆ |
Hot Take | April 19, 2026, 12:58 a.m. EDT
Cardiff Oncology is trapped in a 'binary gamble' between biotech viability and cash flow management; price action in 2025 is showing losses, but the stock is detached from the 52-week low. Leadership stabilizing the team is a critical signaling event, but the lack of any analyst coverage and negative recent performance ratings make this a high-risk, low-probability play for the short term. |
| Model | MAE |
|---|---|
| AutoETS ✓ | 0.460721 |
| AutoARIMA | 0.460722 |
| MSTL | 0.464712 |
| AutoTheta | 0.574697 |
Forecast horizon: 45 days | Selected: AutoETS
| Forecast Reliability | |
|---|---|
| Score | 49% |
| H-stat | 1.11 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.000 |
| Excess Kurtosis | 3.36 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 1.833 |
| Revenue per Share | 0.009 |
| Market Cap | 123,056,952 |
| Forward P/E | -2.57 |
| Beta | 1.42 |
| Website | https://www.cardiffoncology.com |
As of April 19, 2026, 12:58 a.m. EDT: Options activity presents a mixed and defensive signal. Near-term (1-month) expiration shows high Implied Volatility (IV) on both Calls (~3-11%) and Puts (5.5%), indicating hedging or uncertainty rather than a strong directional consensus. The Implied Put/Call Ratio is elevated (~0.8), suggesting a significant amount of hedging buying in the downside. However, Open Interest data reveals a notable concentration of Call options at high strikes (5.0 and 7.5) for the August and January 2028 expirations. This deep out-of-the-money call positioning suggests a speculative 'lottery ticket' thesis: the market is pricing in a potential huge upside if clinical data improves, despite the near-term high IV which punishes convergence. The buy-write spreads (combined short calls/long puts) across 2026 seem lower in premium than the isolated long options, hinting at slight index insurance activity rather than aggressive selling pressure.
| Attribute | Value |
|---|---|
| 52 Week Change | -0.36170214 |
| Address1 | 11,055 Flintkote Avenue |
| All Time High | 2,030.4 |
| All Time Low | 0.7 |
| Ask | 1.82 |
| Ask Size | 9 |
| Audit Risk | 6 |
| Average Daily Volume10 Day | 894,860 |
| Average Daily Volume3 Month | 1,073,329 |
| Average Volume | 1,073,329 |
| Average Volume10Days | 894,860 |
| Beta | 1.419 |
| Bid | 1.79 |
| Bid Size | 9 |
| Board Risk | 5 |
| Book Value | 0.664 |
| City | San Diego |
| Compensation As Of Epoch Date | 1,735,603,200 |
| Compensation Risk | 6 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 1.8 |
| Current Ratio | 3.668 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,774,915,200 |
| Day High | 1.83 |
| Day Low | 1.73 |
| Debt To Equity | 1.833 |
| Display Name | Cardiff Oncology |
| Dividend Date | 1,550,620,800 |
| Earnings Call Timestamp End | 1,740,691,800 |
| Earnings Call Timestamp Start | 1,740,691,800 |
| Earnings Timestamp | 1,771,966,800 |
| Earnings Timestamp End | 1,778,184,000 |
| Earnings Timestamp Start | 1,778,184,000 |
| Ebitda | -48,596,000 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | -1.35 |
| Enterprise To Revenue | 110.599 |
| Enterprise Value | 65,584,964 |
| Eps Current Year | -0.518 |
| Eps Forward | -0.7 |
| Eps Trailing Twelve Months | -0.69 |
| Esg Populated | 0 |
| Exchange | NCM |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 1.724 |
| Fifty Day Average Change | 0.075999975 |
| Fifty Day Average Change Percent | 0.044083513 |
| Fifty Two Week Change Percent | -36.170216 |
| Fifty Two Week High | 4.56 |
| Fifty Two Week High Change | -2.76 |
| Fifty Two Week High Change Percent | -0.6052632 |
| Fifty Two Week Low | 1.48 |
| Fifty Two Week Low Change | 0.31999993 |
| Fifty Two Week Low Change Percent | 0.21621616 |
| Fifty Two Week Range | 1.48 - 4.56 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,090,935,000,000 |
| Float Shares | 66,707,128 |
| Forward Eps | -0.7 |
| Forward P E | -2.5714285 |
| Free Cashflow | -19,617,000 |
| Full Exchange Name | NasdaqCM |
| Full Time Employees | 30 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,775,001,600 |
| Gross Margins | 0.0 |
| Gross Profits | -1,783,000 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.059310004 |
| Held Percent Institutions | 0.36758 |
| Implied Shares Outstanding | 68,364,979 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Last Split Date | 1,550,620,800 |
| Last Split Factor | 1:6 |
| Long Business Summary | Cardiff Oncology, Inc., a clinical-stage biotechnology company, develops novel therapies for the treatment of various cancers in the United States. Its lead drug candidate is Onvansertib, an oral and selective polo-like kinase 1 inhibitor for treating RAS-mutated metastatic colorectal cancer. The company also focuses on the clinical program in indications, such as investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma, small cell lung cancer, metastatic triple negative breast cancer, and chronic myelomonocytic leukemia; CRDF-004, a Phase 2 open-label randomized multi-center clinical trial of onvansertib in combination with FOLFIRI and bevacizumab or FOLFOX and bevacizumab for the treatment of patients confirmed metastatic and unresectable colorectal cancer in patients with a KRAS or NRAS mutation; and TROV-054, a Phase 1b/2 single-arm clinical trial in KRAS-mutated metastatic colorectal cancer. The company was formerly known as Trovagene, Inc. and changed its name to Cardiff Oncology, Inc. in May 2012. Cardiff Oncology, Inc. was founded in 1999 and is headquartered in San Diego, California. |
| Long Name | Cardiff Oncology, Inc. |
| Market | us_market |
| Market Cap | 123,056,952 |
| Market State | CLOSED |
| Max Age | 86,400 |
| Message Board Id | finmb_10959548 |
| Most Recent Quarter | 1,767,139,200 |
| Net Income To Common | -45,876,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 123,056,962 |
| Number Of Analyst Opinions | 8 |
| Open | 1.73 |
| Operating Cashflow | -37,923,000 |
| Operating Margins | -32.20988 |
| Overall Risk | 4 |
| Payout Ratio | 0.0 |
| Phone | 858 952 7570 |
| Post Market Change | 0.029900074 |
| Post Market Change Percent | 1.6611153 |
| Post Market Price | 1.8299 |
| Post Market Time | 1,776,470,351 |
| Previous Close | 1.69 |
| Price Eps Current Year | -3.4749033 |
| Price Hint | 4 |
| Price To Book | 2.7108433 |
| Price To Sales Trailing12 Months | 207.51595 |
| Profit Margins | 0.0 |
| Quick Ratio | 3.586 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | none |
| Region | US |
| Regular Market Change | 0.11 |
| Regular Market Change Percent | 6.50887 |
| Regular Market Day High | 1.83 |
| Regular Market Day Low | 1.73 |
| Regular Market Day Range | 1.73 - 1.83 |
| Regular Market Open | 1.73 |
| Regular Market Previous Close | 1.69 |
| Regular Market Price | 1.8 |
| Regular Market Time | 1,776,456,001 |
| Regular Market Volume | 1,270,500 |
| Return On Assets | -0.38472998 |
| Return On Equity | -0.71454 |
| Revenue Growth | 0.609 |
| Revenue Per Share | 0.009 |
| Sand P52 Week Change | 0.38150132 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 3 |
| Shares Outstanding | 68,364,979 |
| Shares Percent Shares Out | 0.26209998 |
| Shares Short | 17,918,024 |
| Shares Short Previous Month Date | 1,772,150,400 |
| Shares Short Prior Month | 17,680,285 |
| Short Name | Cardiff Oncology, Inc. |
| Short Percent Of Float | 0.2689 |
| Short Ratio | 29.97 |
| Source Interval | 15 |
| State | CA |
| Symbol | CRDF |
| Target High Price | 12.0 |
| Target Low Price | 2.0 |
| Target Mean Price | 7.75 |
| Target Median Price | 9.25 |
| Total Cash | 58,304,000 |
| Total Cash Per Share | 0.853 |
| Total Debt | 832,000 |
| Total Revenue | 593,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -0.69 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 2.33395 |
| Two Hundred Day Average Change | -0.5339501 |
| Two Hundred Day Average Change Percent | -0.2287753 |
| Type Disp | Equity |
| Volume | 1,270,500 |
| Website | https://www.cardiffoncology.com |
| Zip | 92,121 |